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INTRODUCTION
Head and neck squamous cell carcinoma (HN-
SCC) is the sixth most common cancer world-
wide, with more than 600,000 patients diagnosed
with cancer of the oral cavity, oropharynx and
larynx each year (Li et al., 2003). Carcinogenesis
in HNSCC is a multifactorial process, involving
mutations in oncogenes or tumor suppressor
genes, as well as environmental factors such as
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tobacco chewing or smoking, poor oral hygiene,
alcohol abuse, or infection by certain human pa-
pillomavirus (HPV) genotypes (Serefoglou et al.,
2008). More than 180 papillomaviruses have been
identified to date, with approximately 120 geno-
types isolated from humans (Bernard et al., 2010).
The oncogenic types are classified as either high-
or low-risk according to their ability to induce
cancer growth. Most HPV-associated HNSCCs
tend to occur in the oropharynx, with the tonsil
area being the most commonly affected area and
where HPV is present in 45-70% of cases (Mellin
et al., 2002). HPV16 is the predominant genotype
in HNSCC tumors, although its prevalence
changes for different anatomical sites. These dif-
ferent subsets of HNSCC present clinical and mo-
lecular distinctions, as well as distinct patient
The association between human papillomavirus (HPV) DNA positivity, p53 codon 72 polymorphisms, and the type of
leukocyte infiltration in head and neck squamous cell carcinomas (HNSCC) and their combined impact upon patient
survival is poorly investigated. For this reason, leukocyte infiltration profile and p53 codon 72 polymorphisms were
assessed in freshly removed HNSCC specimens (N=71 patients). HPV detection was performed by nested-PCR followed
by DNA sequencing. Viral loads were determined by quantitative RT-PCR. The choice to investigate fresh instead of
archive paraffin-embedded specimens was privileged to avoid possible artifacts due to sample processing. HPV DNA
was detected in 14% of cases. Oropharyngeal carcinomas were the most frequently associated with the presence of
HPV16 DNA (41%) and were associated with p53 Pro/Pro or Pro/Arg polymorphisms. In HPV16-positive oropharyn-
geal carcinomas increased infiltrations of CD3+ and FoxP3+ T-cells correlated with higher HPV16 copy numbers. The
presence of HPV may trigger a stronger immune response and may be considered a reliable marker for clinical stag-
ing and a more favorable prognosis of oropharyngeal carcinoma.
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prognoses. For example, the presence of HPV in
oropharyngeal tumors is associated with more
favorable prognoses compared to HPV-negative
tumors (Chung et al., 2009, Fakhry et al., 2006,
Gillison. 2009, Rautava et al., 2012). 
Molecular studies have shown how expression of
the viral oncoproteins E6 and E7 disrupts crucial
cellular events involved in the control of the cell
cycle and apoptosis. Specifically, the E6 onco-
protein inactivates p53, whereas E7 inactivates
Rb. The p53 protein, encoded by the TP53 gene,
plays a pivotal role in cell regulation pathways,
influencing the transcription and activity of sev-
eral replication and transcription factors. p53 ac-
tivation leads to the induction of DNA repair
mechanisms, the induction of cell cycle arrest,
and the prevention of cancer growth via en-
hanced apoptosis (Orsted et al., 2007). The p53
polymorphism at codon 72 of exon 4, causing an
Arg72Pro substitution in the putative SH3 bind-
ing domain of p53, influences the binding ca-
pacity and functional properties of p53 (Marin et
al., 2000). The Arg (R) allele presents a greater
ability of p53 to locate to mitochondria and in-
duce cell death, whereas the Pro (P) allele exhibits
a lower apoptotic potential and promotes cell cy-
cle arrest in the G1 phase (Dumont et al., 2003,
Pim et al., 2004, Storey et al., 1998). Despite the
greater susceptibility of the Arg72 form to degra-
dation mediated by the HPV-E6 oncoprotein, the
relationship between p53 codon 72 polymor-
phism and HPV-related HNSCC is still unclear.
Some studies have failed to demonstrate a major
role of the p53 polymorphism in head and neck
carcinogenesis (either taken alone or in associa-
tion with HPV status) (Hamel et al., 2000,
McWilliams et al., 2000, Shen et al., 2002), where-
as others have shown that the RP genotype is as-
sociated with a reduced risk of developing
oropharyngeal SCC (Hoffmann et al., 2009,
Perrone et al., 2007). Differences in study sample
size, sampling methods, and geographical distri-
bution may account for the discrepancies re-
ported in the recent literature.
The infiltration of leukocytes into the neoplastic
microenvironment is a common feature of many
epithelial malignancies. For this reason, HNSCC
have been extensively investigated and the strong
inflammatory component of the tumors is well
established. In addition to the presence of
macrophages, a strong degree of T lymphocyte
infiltration, presenting all the components of an
adaptive immune reaction (i.e. CD3, CD4, and
CD8), can be detected in some tumors (Fridman
et al., 2011). In patients with head and neck can-
cers, the antitumor functions of T lymphocytes
are often compromised (Rabinowich et al., 1998,
Reichert et al., 1998), but the presence of func-
tional T-cells, as assessed by the expression of the
CD3-ζ chain or a good proliferative response of
lymphocytes to CD3 antibodies, has been associ-
ated with better patient survival and prognosis
(Badoual et al., 2006). Moreover, the level of reg-
ulatory CD4+CD25+ T-cells has been found to be
elevated in both peripheral blood and tumors of
patients with HNSCC (Strauss et al., 2007).
The present study attempted to verify whether
the presence of HPV associated with the p53
codon 72 polymorphism and the type of leuko-
cyte infiltration could:
1) provide a reliable array of markers capable of
predicting the development of head and neck
tumors;
2) represent a prognostic tool for following tu-
mor progression. For this purpose fresh in-
stead of archive paraffin-embedded specimens
were employed to avoid possible artifacts due
to sample processing.
MATERIALS AND METHODS
Patients
Investigations involved 71 patients with primary
SCCs of the head and neck district, diagnosed
and treated in the Department of Otolaryngology,
San Giovanni Battista Hospital, Turin, between
2005 and 2010. Written informed consent was
obtained from the patients, and ethical approval
for this study was granted by the San Giovanni
Battista Hospital Research Ethics Committee,
Turin. The present study was conducted accord-
ing to the Declaration of Helsinki principles.
All the patients underwent surgery as first-line
treatment. All the tumors included in the study
were histopathologically diagnosed as squamous
cell carcinoma. Tumors were staged according to
the AJCC/UICC TNM Staging System 2009 (Sobin
et al., 2009). Information on patient tobacco and
alcohol consumption was obtained from patient
medical files. Patients who currently smoke were
classified as light (<10 cigs/day), medium (10-20
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cigs/day), heavy (>20 cigs/day) or non-smokers.
Patients were classified as moderate, heavy, or
non-drinkers, according to the American Dietary
Guidelines on alcohol consumption (Services et
al., 2005).
Tumor samples
Tumor samples were collected at the time of sur-
gery. A fragment was excised and immediately
snap-frozen in liquid nitrogen and stored at -70°C.
The tissue specimens comprising the remaining
tumor tissue were fixed in buffered formaldehyde
4% and paraffin-embedded for histopathological
analysis. All specimens were stained with hema-
toxylin and eosin to determine histology and an-
alyzed by two independent pathologists. 
DNA extraction, HPV detection and viral
load determination
DNA extraction from fresh-frozen samples was
performed by using the Nucleo Spin Tissue ex-
traction kit (Machery-Nagel, Germany), and in
accordance with the manufacturer’s protocol. All
specimens were examined by β-globin PCR to es-
timate the quantity of DNA and to control its
quality, as previously described (Rittà et al., 2009). 
HPV DNA analysis was performed by nested PCR
assays, using MY09/MY11 as the outer and
GP5+/GP6+ as the inner primers, the latter am-
plifying a 140-bp fragment within the HPV L1
open reading frame (Fuessel Haws et al., 2004,
Rittà et al., 2009). All PCR reactions were carried
out using REDTaq ReadyMix PCR Reaction Mix
(Sigma-Aldrich). 
Positive PCR products were purified using a pu-
rification kit (NucleoSpin Extract II, Macherey
Nagel) and verified by direct sequencing with the
GP5+ primer on a DNA sequencer (PRIMM,
Milan, Italy). HPV genotypes were determined on
the basis of >95% homology with sequences de-
posited in GenBank using the BLAST network
service at NCBI (http://blast.ncbi.nlm.nih.gov/).
Tumor DNA p53 codon 72 polymorphisms were
genotyped using PCR followed by Restriction
Fragment Length Polymorphism (RFLP) analy-
sis. Amplifications were performed with the
primers 5’-ATCTACAGTCCCCCTTGCCG-3’ and
5’-GCAACTGACCGTGCAAGTCA-3’. The PCR re-
action was performed in a 25 µL final volume,
containing 25 pmol of each primer, ~100 ng of
extracted DNA, and 12.5 µL of Ready Mix PCR
Reaction Mix (Sigma). The PCR thermal profile
comprised an initial denaturation for 4 minutes
at 94°C, followed by 30 cycles of: 94°C for 40 sec,
56°C for 30 sec, and 72°C for 40 sec; a final elon-
gation step occurred at 72°C for 10 min. The re-
action products were digested with Bsh1236I
(BstUI) (Fermentas, Vilnius, LT) for 3 hours at
37°C. The digested DNA was subjected to elec-
trophoresis in 2% agarose gels, followed by ethid-
ium bromide staining. The Pro allele resulted in
an undigested 296-bp band, whereas the Arg allele
was indicated by the presence of two bands of
169 and 127 bp (Ji et al., 2008, Li et al., 2010).
To determine HPV16 load, a type specific Q-PCR
protocol was performed with Maxima SYBR
Green/ROX qPCR Master Mix (Fermentas) ac-
cording to the manufacturer’s instructions, using
the Mx3000P thermocycler (Stratagene). A spe-
cific primer set was designed to amplify the E7 re-
gion of HPV16 (5’-GAGATACACCTACATTGC-3’
and 5’-CACACAATTCCTAGTGTG-3’). A Standard
curve was generated in the same PCR run with
HPV16 plasmid dilutions ranging from 1 to 106
copies per sample in an HPV-negative human
DNA solution. To correct for PCR efficiency and
DNA integrity and to determine the number of
input cell equivalents, the gene GAPDH was
quantified using the following primers: 5’-
AACGTGTCAGTGGTGGACCTG-3’ and 5’-
AGTGGGTGTCGCTGTTGAAGT-3’. The samples
were run in duplicate and the final result ex-
pressed as the number of HPV16 copies per cell.
Immunohistochemistry (IHC)
IHC was performed on formalin-fixed and paraf-
fin-embedded biopsy samples (2 µm-thick), us-
ing the completely automated Leica BOND-
MAX™ instrument. The following antibodies
were applied: anti-CD3 (clone PS1, working di-
lution 1:50; Novocastra, Newcastle Upon Tyne,
UK); anti-CD4 (clone 1F6, working dilution 1:40;
Novocastra); anti-CD25 (clone 4C9, working di-
lution 1:50; Novocastra); anti-CD8 (clone
C8/144B, working dilution 1:50; DakoCytomation,
Denmark); anti-CD20 (clone L26, working dilu-
tion 1:200; DakoCytomation); anti-CD68 PGM1
(clone PGM1, working dilution 1:50;
DakoCytomation); anti-FoxP3 (clone 236A/E7,
working dilution 1:100; eBioscience, Inc. San
Diego, CA, USA). Immunostaining was evaluat-
ed by three independent pathologists (MR, JM
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and VL). To confirm the reproducibility, 25% of
the slides were selected at random and scored
twice. Positive cells were stained dark brown with
cytoplasmic positivity for CD3, CD4, CD8, CD25,
CD20, CD68 PGM1 and nuclear for FoxP3.
Numbers of labeled tumor infiltrating cells are
reported as percentages of positively stained tu-
mor infiltrating cells. 
Statistical and overall survival analysis
All statistical tests were performed using
GraphPad Prism version 5.00 for Windows. Chi-
square and Fisher’s exact test were used to test
for differences between the groups. The Kaplan
Meyer method was used to estimate survival
curves, which were compared using a 2-sided log-
rank test. Overall patient survival times were de-
fined as the interval between the date of surgery
and the last date when the patient was known to
be alive or the date of death for any reason.
RESULTS
Clinical-pathological features
The 71 lesions included 22 cases of SCC located
in the oropharynx (31%), 22 SCC in the oral cav-
ity (31%) and 27 cases in the larynx (38%). The
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TABLE 1 - HPV status and clinical and histopathological parameters of the HNSCC patients.
HPV status
patients HPV negative HPV positive p value
no. (%)* no. (%)* no. (%)*
Gender female 12 (16.9) 9 (12.7) 3 (4.2)
male 59 (83.1) 52 (73.2) 7 (9.9) 0.3565
Smoking non smokers 10 (14.1) 7 (9.9) 3 (4.2)
<10 cigs/day 9 (12.7) 7 (9.9) 2 (2.8)
10-20 cigs/day 25 (35.2) 20 (28.2) 5 (7)
>20 cigs/day 27 (38) 27 (38) 0 0.0518
Alcohol consumption no 16 (22.5) 15 (21.1) 1 (1.4)
moderate 46 (64.8) 38 (53.5) 8 (11.3)
heavy 9 (12.7) 8 (11.3) 1 (1.4) 0.5239
Tumor site oral cavity 22 (31) 21 (29.6) 1 (1.4)
oropharynx 22 (31) 13 (18.3) 9 (12.7)
larynx 27 (38) 27 (38) 0 <0.0001
Grading of differentiation g1 12 (16.9) 12 (16.9) 0
g2 42 (59.2) 35 (49.3) 7 (9.9)
g3 17 (23.9) 14 (19.7) 3 (4.2) 0.3047
T classification T1 15 (21.1) 13 (18.3) 2 (2.8)
T2 29 (40.8) 24 (33.8) 5 (7)
T3 13 (18.3) 11 (15.5) 2 (2.8)
T4 14 (19.7) 13 (18.3) 1 (1.4) 0.8443
N classification N0 32 (45.1) 30 (42.3) 2 (2.8)
N1 10 (14.1) 7 (9.9) 3 (4.2)
N2 29 (40.8) 24 (33.8) 5 (7) 0.1384
M classification M0 71 (100) 61 (85.9) 10 (14.1)
M1 0 0 0 NA
Age at diagnosis (mean) 61 yrs 61.9 yrs 0.8116
*Number of patients (percentage of patients).
average age of the patients was 68 years for fe-
males (range 55-80) and 60 years for males (range
38-85); total number of females was 12, compared
to 59 males. The characteristics of the study
group and the histopathologic parameters are
summarised in Table 1.
HPV DNA detection and viral load analysis
The global prevalence of HPV in HNSCC and its
distribution across the various anatomical carci-
noma sites remain unclear. The frequency of
HPV-positive tumors in HNSCC varies depend-
ing on the population studied, the location of the
tumors, and the HPV detection method used
(Kreimer et al., 2005, Wang et al., 2012). The re-
sults of PCR-based HPV detection methods may
be influenced by the anatomical source of the
clinical specimen and by the DNA-extraction
method used, since the nucleic acids in formalin-
fixed, paraffin-embedded tissues are only ampli-
fied in a reliable manner when PCR products are
generated that are smaller than 150-bp due to fix-
ative-induced cross links (Brink et al., 2007). In
the present study, the prevalence of HPV infec-
tion was therefore investigated only using fresh-
frozen specimens to avoid the pitfalls caused by
the use of formalin and paraffin reagents. As a
consequence, the number of samples processed is
lower, but still reliable for a correct statistical
analysis.
All 71 frozen-tissue samples turned out to be β-
globin positive, and were consequently investi-
gated using high sensitivity nested-PCR for HPV
detection; MY09-MY11 were used as the outer
and GP5+-GP6+ as the inner primers. HPV DNA
was detected in 10 of the 71 cases (14%).
Sequencing revealed all 10 HPV DNA-positive
samples to be infected by HPV16, with only one
case of co-infection by HPV16 and HPV33.
Oropharyngeal carcinomas turned out to have
the highest HPV incidence, with 9 out of 22 cas-
es (41%) positive for HPV16. The oropharyngeal
SCC positive for both HPV16 and HPV33 was lo-
calized to a tonsil. The tenth case of HPV16 in-
fection was located to the oral cavity, and was the
only one of the 22 cases of carcinoma arising in
the oral cavity to be positive for HPV-positivity
(4.5%). In carcinomas of the larynx, HPV was not
detected in any of the 27 cases analyzed. 
The viral load in all 10 HPV-positive cases was
quantifiable and showed great variability (rang-
ing between 7.4*10-4 and 4.56 HPV16 copies per
cell), with the highest value detected in an
oropharyngeal carcinoma involving the tonsil and
the base of tongue, and the lowest in a carcinoma
of the oral cavity (tongue). No correlation was
found between gender, age at diagnosis, TNM
classification, grading of differentiation, or HPV
infection. A significant correlation was observed
between the smoking history and the presence of
HPV-DNA: in the cohort of heavy smokers (de-
fined as smoking more than 20 cigarettes a day),
no case of HPV infection was found. Only in pa-
tients with a smoking history of less than 20 cig-
arettes a day (7 cases) and in non-smokers (3 cas-
es) was HPV DNA found (p=0.0518). The history
of alcohol consumption did not seem to be relat-
ed to the presence of HPV DNA in tumors. All da-
ta are reported in Table 1.
p53 codon 72 polymorphism
The tumor suppressor protein p53 can be bound,
degraded and inactivated by the human HPV16
E6 oncoprotein (Scheffner et al., 1990). The sus-
ceptibility of p53 to the HPV16 oncoprotein may
be influenced by the p53 codon 72 polymorphism
(Ji et al., 2008). To analyze the p53 status in our
cohort of patients, p53 RFLP analysis was per-
formed on all 71 tumor specimens; the results are
displayed in Table 2. The homozygous allele for
p53 Arg was the most commonly detected (32 cas-
es: 45.1%); 30 tumors (42.3%) possessed the het-
erozygous genotype (p53 Arg/Pro) and 9 cases
(12.6%) were homozygous for p53 Pro. No cor-
relations were found between p53 polymorphism
genotype and tumor site, grading, TNM staging or
any other clinical-pathological feature (Table 2).
Nevertheless, a significant association was ob-
served between p53 codon 72 polymorphism and
the presence of HPV. As shown in Table 3, the
majority of HPV-positive tumors presented a
Pro/Arg p53 polymorphism at codon 72 (8 out of
10 HPV-positive tumors, p=0.0278). RFLP analy-
sis revealed that 8 out of 9 HPV16-positive
oropharyngeal carcinomas possessed the p53
Pro/Arg allele; with the ninth case being Pro/Pro
(p=0.0217). This association between HVP-posi-
tivity and p53 polymorphisms in oropharyngeal
carcinomas was maintained when we compared
the HPV profiles of Pro/Pro and Pro/Arg patients
against those of Arg/Arg patients: collectively, 9
of the 17 PP/PR patients turned out to be HPV16
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TABLE 2 - p53 codon 72 polymorphisms according to clinical and histopathological parameters 
of the HNSCC patients.
p53 codon 72 polymorphism
patients Pro/Pro Pro/Arg Arg/Arg p value
no. (%)* no. (%)* no. (%)* no. (%)*
Gender female 12 (16.9) 0 5 (7) 7 (9.9)
male 59 (83.1) 9 (12.7) 25 (35.2) 25 (35.2) 0.3019
Smoking no smoking 10 (14.1) 1 (1.4) 4 (5.6) 5 (7)
<10 cigs/day 9 (12.7) 1 (1.4) 2 (2.8) 6 (8.5)
10-20 cigs/day 25 (35.2) 4 (5.6) 15 (21.1) 6 (8.5)
>20 cigs/day 27 (38) 3 (4.2) 9 (12.7) 15 (21.1) 0.261
Alcohol consumption no 16 (22.5) 2 (2.8) 8 (11.3) 6 (8.5)
moderate 46  (64.8) 6 (8.5) 19 (26.8) 21 (29.6)
heavy 9 (12.7) 1 (1.4) 3 (4.2) 5 (7) 0.9308
Tumor site oral cavity 22 (31) 1 (1.4) 7 (9.9) 14 (19.7)
oropharynx 22 (31) 5 (7) 12 (16.9) 5 (7)
larynx 27 (38) 3 (4.2) 11 (15.5) 13 (18.3) 0.0750
Grading of differentiation g1 12 (16.9) 1 (1.4) 3 (4.2) 8 (11.3)
g2 42 (59.2) 5 (7) 18 (25.4) 19 (26.8)
g3 17 (23.9) 3 (4.2) 9 (12.7) 5 (7) 0.4053
T classification T1 15 (21.1) 5 (7) 5 (7) 5 (7)
T2 29 (39.4) 3 (4.2) 13 (18.3) 13 (18.3)
T3 13 (18.3) 1 (1.4) 7 (9.9) 5 (7)
T4 14 (19.7) 0 5 (7) 9 (12.7) 0.1325
N classification N0 32 (45.1) 4 (5.6) 11 (15.5) 17 (23.9)
N1 10 (14.1) 2 (2.8) 4 (5.6) 4 (5.6)
N2 29 (40.8) 3 (4.2) 15 (21.1) 11 (15.5) 0.6461
M classification M0 71 (100) 9 (12.7) 30 (42.3) 32 (45)
M1 0 0 0 0 NA
Age at diagnosis (mean) 61.7 yrs 61.7 yrs 61.4 yrs 0.9943
* Number of patients (percentage of patients).
TABLE 3 - Distribution of p53 codon 72 polymorphisms according to HPV status in the three anatomic sites.
p53 codon 72 polymorphism
Pro/Pro Pro/Arg Arg/Arg p value
no. (%)* no. (%)* no. (%)*
Oropharynx carcinoma
HPV neg 4 (18.2) 4 (18.2) 5 (22.7)
HPV pos 1 (4.5) 8 (36.4) 0 0.0217
Oral cavity carcinoma
HPV neg 1 (4.5) 7 (31.8) 13 (59.1)
HPV pos 0 0 1 (4.5) 0.7413
Larynx carcinoma
HPV neg 3 (11.1) 11 (40.7) 13 (48.2)
HPV pos 0 0 0 NA
*Number of patients (percentage of patients).
positive, whereas none of the 5 Arg/Arg cases
were HPV positive (p=0.0343, data not reported). 
Immunohistochemical analysis
Many studies report the presence of tumor-infil-
trating lymphocytes (TILs) as representing a sur-
vival factor in HNSCC (Fridman et al., 2011).
Moreover, FoxP3+CD4+ T-cells positively influ-
ence locoregional control in patients with head
and neck cancers by down-regulating harmful in-
flammatory reactions known to favor tumor pro-
gression (Badoual et al., 2006). In an attempt to
verify the role of HPV infection on TIL frequen-
cy and phenotype, IHC analysis was performed
on the 22 cases of oropharyngeal SCC. The re-
sults of the immunohistochemical assays are il-
lustrated in Figure 1. No difference was found in
the extent of tumor infiltration by CD25+,
FoxP3+, CD3+, C68+, CD20+, CD8+, or CD4+
cells in HPV-positive versus HPV-negative tumors.
The results are summarized in Table 4. Moreover,
no significant correlations were found between
the TIL subpopulations present in the tumors and
their pathological classifications, as determined
by grading and TNM status (data not shown).
Viral loads were determined in the HPV16-posi-
tive oropharyngeal carcinomas in an attempt to
verify whether they were correlated with the phe-
notype of TILs present. HPV16 load values equal
or greater than 10-1 copies per cell were associat-
ed with higher densities of tumor infiltrating
CD3+ and FoxP3+ cells. The mean density of
FoxP3+ cells was 52.5% for carcinomas with
HPV16 viral loads ≥10-1 copies/cell, and 27.5% in
carcinomas with HPV16 viral loads <10-1
copies/cell (p=0.0469). A similar correlation was
found for CD3+ tumor infiltrating cells, with
mean densities of 80% and 37.6% for carcinomas
with HPV16 viral loads ≥10-1 and <10-1 copies/cell,
respectively (p=0.0352). Data are summarized in
Table 5.
Prognosis
Among the patients presenting oropharyngeal
carcinomas, those with tumors positive for
HPV16 turned out to have better clinical out-
comes than those negative for HPV. Kaplan-Meier
analysis showed that patients with HPV16-posi-
tive tumors had significantly better overall sur-
vival rates than patients with HPV-negative tu-
mors (p=0.0468). The median survival time was
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FIGURE 1 -Representative immunohistochemical stain-
ing of CD3+, CD4+, CD8+, CD25+, FoxP3+, CD20+, and
CD68+ tumor-infiltrating cells in low-expressing (left
panels) and high-expressing (right panels) HNSCC.
Immunohistochemical staining shows positive cells in
brown, counterstained with hematoxylin (original mag-
nification 200X).
46 months in the HPV-negative group, whereas
it was undefined in the HPV-positive group
(Figure 2). Focusing on the HPV-positive oropha-
ryngeal carcinomas, the HPV16 viral load values
(as determined by quantitative RT-PCR) did not
turn out to represent a significant predictor of
clinical outcome (data not shown). A survival
analysis was also performed with respect to the
p53 codon 72 polymorphism results. The genet-
ic polymorphisms were not associated with any
clinical outcomes in any carcinoma subgroup
(p=0.7548, p=0.2612, and p=0.7491 for carcino-
mas located to the oropharynx, oral cavity, and
larynx respectively).
DISCUSSION
Increasing epidemiological evidence posits the
existence of a subgroup of head and neck cancers
localized to the oropharynx that are causally as-
sociated with HPV infection, and that are char-
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TABLE 5 - Mean density of tumor infiltrates in low- and high-HPV16 viral load oropharyngeal carcinomas.
Low-HPV16 viral load High-HPV16 viral load p value
carcinomas (<10-1 copies/cell) carcinomas (≥10-1 copies/cell)
(mean density)* (mean density)* 
CD3+ 37.6% 80% 0.0352
CD4+ 51.3% 61% 0.4037
CD8+ 40% 45% 0.8640
CD25+ 48% 58.2% 0.2249
FoxP3+ 27.5% 52.5% 0.0469
CD20+ 17.3% 54% 0.0742
CD68+ 59.3% 75% 0.5625
*Mean density of tumor infiltrating leukocytes.
TABLE 4 - Differences between HPV-positive and -negative oropharyngeal carcinomas with respect to tumor
infiltrates.
HPV+ oropharynx carcinomas HPV- oropharynx carcinomas p value
(mean density)* (mean density)*
CD3+ 49.3% 35% 0.3198
CD4+ 55% 37.1% 0.2932
CD8+ 41.7% 26.8% 0.3012
CD25+ 50.1% 34.8% 0.1977
FoxP3+ 40% 31.7% 0.5540
CD20+ 29.5% 28.8% 0.9558
CD68+ 64.5% 58.5% 0.7232
*Mean density of tumor infiltrating leukocytes.
acterized by a markedly better prognosis than
that for HPV-negative tumors arising in the same
anatomical area (Gillespie et al., 2009). In an at-
tempt to disclose, at least in part, the mechanisms
responsible for this favorable response, the pres-
ent study investigated the potential correlations
between the presence of HPV and the tumor pro-
files of infiltrating leukocytes and p53 codon 72
polymorphisms. Both of these parameters have
been shown to correlate with favorable prognosis
of the oropharynx carcinoma (Li et al., 2010). To
avoid possible artifacts due to sample processing
we decided to use fresh instead of archive paraf-
fin-embedded samples. As a consequence, the
number of samples available was lower, but still
suitable for a correct statistical analysis.
The results obtained with fresh frozen samples
showed how patients with oropharyngeal carci-
noma harboring HPV16 exhibited a better overall
survival (5 year follow-up) than those negative for
HPV (p=0.0468). This finding is in line with re-
cent reports (Gillison. 2006, Hansson et al., 2005,
Mannarini et al., 2009, Mork et al., 2001) showing
that HPV infection of oropharyngeal carcinomas
is associated with a reduced risk of relapse and
second tumors compared to HPV-negative tu-
mors. The mechanisms underlying the improved
clinical outcome of HPV-positive SCC are still un-
clear. A few studies have suggested that the bet-
ter prognosis could be related to an enhanced ra-
diosensitivity of HPV-positive SCC compared to
HPV-negative ones. Furthermore, HPV16 positive
HNSCC are more likely to carry wild type TP53
and express p16. The presence of functional TP53
in HPV-positive HNSCC may render the tumors
susceptible to radiation-induced apoptosis.
Another reason appears to be the absence of car-
cinogen-induced early genetic changes in the ep-
ithelium and the development of multifocal tu-
mors (the so-called “field cancerization”)
(Mannarini et al., 2009, Slaughter et al., 1953).
Recent studies have shown that patients with
HPV16-positive HNSCC expressing wild-type
TP53 or p16 have improved disease-free survival,
supporting the notion that the improved prog-
nosis may in fact be related to HPV infection. We
found a significant association between the pres-
ence of the p53 Pro/Pro or Pro/Arg polymorphism
and the presence of the HPV16 genome in the
subgroup of oropharyngeal carcinomas. Indeed,
all of the 9 HPV-positive tumors arising in the
oropharynx presented the p53 Pro allele
(p=0.0343). This finding is in agreement with the
hypothesis that the Pro allele may enhance the
carcinogenetic potential of head and neck HPV-
positive cells, which may also be related to the
reduced capacity of the Pro72 form of p53 to in-
duce apoptosis compared to Arg72 form.
Consistent with our results, Perrone et al. report-
ed a greater frequency of p53 Pro homozygosity
in their HPV-positive tumor group, and postulat-
ed the presence of the p53 Pro allele as being a
risk factor for the development of HPV-associat-
ed oropharyngeal SCC (Perrone et al., 2007).
Moreover, in line with our finding, Ji et al. (Ji et
al., 2008) demonstrated that HPV16 seropositiv-
ity was associated with an increased risk of squa-
mous cell carcinoma of the oropharynx, espe-
cially among never-smokers and subjects with the
p53 codon 72 Arg/Pro and Pro/Pro genotypes.
Altogether, these results suggest that the p53
codon 72 variant genotypes modify the risk of
HPV16-associated SCC of the oropharynx, espe-
cially among never-smokers.
In humans, regulatory CD4+CD25+ T-cells have
been found to be increased in tumor-infiltrating
lymphocytes and in the peripheral circulation of
patients with various malignancies, including
head and neck cancer (Badoual et al., 2006,
Schaefer et al., 2005). In non-small cell lung can-
cer (NSCLC) there is a marked infiltration of dif-
ferent types of immune cells, and the distribu-
tion, tissue localization, and cell types are signif-
icantly associated with cancer progression and
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FIGURE 2 - Cumulative prognostic value of human pa-
pillomavirus (HPV) positivity for patients with squa-
mous cell carcinoma of the oropharynx, expressed as
probability of overall survival. 
patient survival (Bremnes et al., 2011). However,
the accumulation of T-regs in various human car-
cinomas is generally associated with a poor prog-
nosis, as they are expected to inhibit anti-tumor
immune responses (Ladoire et al., 2011). In he-
patocellular carcinoma, it has indeed been re-
ported that the prevalence of tumor-infiltrating
T-regs significantly increases in a stepwise man-
ner during the progression of hepatocarcinogen-
esis, whereas the prevalence of tumor infiltrating
CD8+ T lymphocytes decreases significantly with
disease progression (Hiraoka 2010). This rela-
tionship has also been reported in a wide range
of localized or metastatic human carcinomas, in-
cluding breast (Bates et al., 2006), ovarian (Curiel
et al., 2004), lung (Petersen et al., 2006), renal cell
(Li et al., 2009), pancreatic (Hiraoka et al., 2006),
and gastric carcinomas (Perrone et al., 2008).
However, conflicting data have accumulated sug-
gesting that high tumor infiltration by FoxP3+ T-
regs is not always associated with a poor prog-
nosis, but, on the contrary, can be associated with
an improved prognosis in some cancer types.
Indeed, in the context of colorectal carcinoma,
various studies have demonstrated the favorable
prognostic importance of CD8+ and CD45R0+ T-
cell densities, the associated high degree of tu-
mor infiltration with FoxP3+ T-cells, and better
patient survival (Ladoire et al., 2011). The pres-
ence of FoxP3+ CD4+ regulatory T-cells may also
be linked with better locoregional control in HN-
SCC, most likely involving the down-regulation
of an inflammatory reaction, but which could al-
so favor tumor progression (Badoual et al., 2006,
Balkwill et al., 2004, Schaefer et al., 2005). In our
study, no correlation between CD3+ and FoxP3+
T-cells and a favorable patient follow-up was ob-
served. However, a significantly higher level of
CD3+ and FoxP3+ T-cell infiltration was observed
in oropharyngeal tumors displaying high HPV16
copy numbers. As oropharyngeal carcinomas har-
boring HPV16 exhibit a better overall survival, it
is conceivable that the presence of HPV may trig-
ger a stronger immune response responsible for
a more favorable prognosis of the tumors arising
in this anatomical site.
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